Childhood Cancer Survivors COVID-19 Risk
Childhood Cancer Survivors Face Higher Risk of Severe COVID-19, Despite Lower infection rates
Table of Contents
Childhood cancer survivors exhibit a heightened vulnerability to severe COVID-19 outcomes, even while demonstrating a lower risk of initial infection compared to the general population. Recent research underscores the importance of recognizing this population as high-risk during ongoing and future public health crises, emphasizing the need for proactive preventative measures and targeted support.
Increased Severity, Lower Infection Risk: A Complex Picture
A large, register-based cohort study conducted in Denmark and sweden revealed a substantially elevated risk of severe COVID-19 among individuals who survived childhood cancer. Utilizing adjusted Cox proportional hazards regression models, researchers found a 58% increase in the hazard ratio for severe illness (aHR = 1.58 [95% CI, 1.25-1.98]) when compared to matched controls.
Interestingly,the study also demonstrated that childhood cancer survivors were less likely to contract COVID-19 in the first place (aHR = 0.91 [95% CI, 0.89-0.94]). This seemingly paradoxical finding suggests that survivors may be more diligent in adopting preventative behaviors, such as masking, social distancing, and staying current with vaccinations.
Factors Influencing Risk
The increased risk of severe COVID-19 wasn’t uniform across all survivors. The study identified several key factors that amplified vulnerability:
Age: Survivors aged 50 or older at the study baseline faced a more pronounced risk increase. Geographic Location: Survivors in Sweden exhibited a higher risk compared to those in Denmark.
Tumor Type: Individuals who had survived solid tumors were at greater risk than those who had leukemia or lymphoma.
Age at Diagnosis: Survivors diagnosed with cancer at age 15 or older experienced a more meaningful increase in risk.
These findings highlight the importance of considering individual patient characteristics when assessing risk and tailoring preventative strategies. long-term effects of cancer treatment, including potential impacts on immune function and organ systems, likely contribute to this increased susceptibility.
Implications for Pharmacists and Public Health
“It is significant to understand that even though these individuals were not infected more often, the consequences were more serious when they did become ill,” explains Javier Louro, postdoctoral researcher at the Institute of Environmental Medicine at Karolinska Institutet and lead author of the study.
Pharmacists play a crucial role in bridging the gap between research findings and patient care. They are uniquely positioned to counsel childhood cancer survivors on their elevated risk and empower them with knowlege about proactive steps they can take to mitigate that risk. This includes:
Vaccination: Ensuring survivors are up-to-date on all recommended COVID-19 vaccinations and boosters.
Preventative Measures: Reinforcing the importance of masking in crowded indoor settings, practicing good hand hygiene, and maintaining social distancing.
Early Intervention: Educating survivors about the signs and symptoms of COVID-19 and encouraging prompt medical attention if symptoms develop.
Medication Review: Assessing potential drug interactions between COVID-19 treatments and medications survivors may be taking for long-term effects of cancer treatment.
Looking ahead, researchers emphasize the need to proactively identify and protect vulnerable populations during future pandemics. “our results suggest that childhood cancer survivors should be considered a risk group in future pandemics or other health crises,” Louro stated. ”This could involve prioritizing them for vaccination or offering special protection during periods of high transmission.”
By recognizing the unique vulnerabilities of this population and implementing targeted interventions, we can strive to minimize the disproportionate impact of future health crises on childhood cancer survivors.
REFERENCES
- Louro J, Kampitsi C, Mogensen H, et al. COVID-19 infection and severity among childhood cancer survivors in Denmark and Sweden: a register-based cohort study with matched population and sibling comparisons. The Lancet. 2025; 55: 101363. DOI: 10.1016/J.lanepe.2025.101363
- Guilcher GMT, Rivard L, Huang JT, et al. Immune function in childhood cancer survivors: a children’s Oncology Group review.The Lancet. 2021;5(4):284-294. doi:10.1016/S235